investorscraft@gmail.com

Intrinsic value of ChromaDex Corporation (CDXC)

Previous Close$1.46
Intrinsic Value
Upside potential
Previous Close
$1.46

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh7.52 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %13.8NaN
Revenue, $67NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m95NaN
Operating income, $m-27NaN
EBITDA, $m-25NaN
Interest expense (income), $mNaN
Earnings before tax, $m-27NaN
Tax expense, $m0NaN
Net income, $m-27NaN

BALANCE SHEET

Cash and short-term investments, $m28NaN
Total assets, $m58NaN
Adjusted assets (=assets-cash), $m30NaN
Average production assets, $m4NaN
Working capital, $m31NaN
Total debt, $m5NaN
Total liabilities, $m26NaN
Total equity, $m32NaN
Debt-to-equity ratio0.148NaN
Adjusted equity ratio0.137NaN

CASH FLOW

Net income, $m-27NaN
Depreciation, amort., depletion, $m2NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-24NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-23NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m31
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount